FLT3 and acute myeloid leukemia: Some of the most prominent examples of targeted therapies in AML are inhibitors of the FMS-like tyrosine kinase (FLT3) which is recurrently mutated by internal tandem duplications (ITD) in up to 25% of adults (Perl et al., 2017; Stone et al., 2017).